3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
103
Lymphoma
68
Lymphoma, Large B-Cell, Diffuse
49
Precursor Cell Lymphoblastic Leukemia-Lymphoma
41
Sarcoma
33
Lymphoma, Non-Hodgkin
29
Hodgkin Disease
28
Leukemia
23
Burkitt Lymphoma
22
Neoplasms
19
Lymphoma, Mantle-Cell
18
Triple Negative Breast Neoplasms
15
Multiple Myeloma
15
Lymphoma, Follicular
15
Lymphoma, B-Cell
14
Lymphoma, Large-Cell, Anaplastic
12
Carcinoma, Hepatocellular
12
Breast Neoplasms, Male
11
Neuroblastoma
10
Recurrence
9
Ovarian Neoplasms
9
Neoplasm Metastasis
9
Inflammatory Breast Neoplasms
9
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
8
Lymphoma, T-Cell, Peripheral
8
Lymphoma, T-Cell
8
Osteosarcoma
7
Fallopian Tube Neoplasms
7
Urinary Bladder Neoplasms
6
Liposarcoma
6
Interventions
fluciclovine F-18
2
Positron-Emission Tomography
2
Injections
2
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
2
pembrolizumab
1
ioflupane
1
idelalisib
1
aflibercept
1
Water
1
Vertical Dimension
1
Methylene Blue
1
Mammography
1
Drug Delivery Systems
1
Diagnosis, Computer-Assisted
1
Daunorubicin
1
Cytarabine
1
Control Groups
1
CPX-351
1
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Disease
×
Doxorubicin
×
Clear all
No trials found.